Against cancer
Starton Therapeutics is a biotechnology company that developed a technology platform to improve the quality of life of people with cancer. Its founder, the Mexican Pedro Lichtinger, poured his 28 years of experience in the pharmaceutical field into the creation of a transdermal patch made from a reformulation of the drug REVLIMID® (lenalidomide), the star drug in the treatment of hematological cancer.
The advantage of the patch over oral administration of the drug is that it allows continuous release of the drug in low doses, which makes it more tolerable and effective. Starton’s patch has already shown positive results in phase 1 of its clinical study and is moving towards phase 1b/2.
ThyroidPrint® is a test that determines if a thyroid nodule is cancerous or not without having to resort to surgery. It was created at GeneproDX, a clinical laboratory dedicated to molecular diagnosis directed by the Chilean doctor Hernán González.
From a sample of the indeterminate nodule, ThyroidPrint analyzes the information from 10 genetic markers using an algorithm developed with artificial intelligence. The result, which is obtained in approximately two hours, has a predictive value of 96%, which avoids unnecessary thyroid surgeries that, in addition to being costly for the entire health system, leave patients hormone-dependent for life.
ThyroidPrint already has a place among other approved oncology tests, such as those that identify breast, colorectal or dermatological pathologies. All of them are more precise, faster, cheaper and less invasive than the protocols we followed until today.
